Key cancer cell signal transduction pathways as therapeutic targets
- 1 February 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (3) , 290-294
- https://doi.org/10.1016/j.ejca.2005.07.034
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future DirectionsJournal of Clinical Oncology, 2005
- Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cellsEndocrine-Related Cancer, 2004
- Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?Cancer Cell, 2004
- Biologic and therapeutic role of HER2 in cancerOncogene, 2003
- Antisense strategies targeting protein kinase C: preclinical and clinical developmentSeminars in Oncology, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Understanding Ras: ‘it ain’t over ’til it’s over’Trends in Cell Biology, 2000
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000